Structural and kinetic features of amyloid β-protein fibrillogenesis

Amyloid

Volumn 5, Issue 2, 1998, Pages 121-142

  Teplow, David B ^a,b  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Alzheimer's disease; Amyloid protein; Amyloidogenesis; Fibrillogenesis; Kinetics; Transthyretin

Indexed keywords

AMYLOID BETA PROTEIN; BIOPOLYMER;

AMINO ACID SEQUENCE; BIOSYNTHESIS; HUMAN; KINETICS; PROTEIN CONFORMATION; REVIEW; STRUCTURE ACTIVITY RELATION;

AMINO ACID SEQUENCE; AMYLOID BETA-PROTEIN; BIOPOLYMERS; HUMANS; KINETICS; PROTEIN CONFORMATION; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 0032084472     PISSN: 13506129     EISSN: None     Source Type: Journal    
DOI: 10.3109/13506129808995290     Document Type: Article

References (223)

1. Glenner GG (1980). Amyloid deposits and amyloidosis. The β-fibrilloses (First of two parts). New Eng J Med 302, 1283-1292
2. Selkoe DJ (1991). Amyloid protein and Alzheimer's disease. Sci Am 265, 68-71, 74-6, 78
3. Mega MS, Cummings JL, Fiorello T and Gornbein J (1996). The spectrum of behavioral changes in Alzheimer's disease. Neurology 46, 130-135
4. Selkoe DJ (1991). The molecular pathology of Alzheimer's disease. Neuron 6, 487-498
5. Iqbal K (1991). Prevalence and neurobiology of Alzheimer's disease. In: Alzheimer's Disease: Basic Mechanisms, Diagnosis and Therapeutic Strategies. (K. Iqbal, D.R.C. McLachlan, B. Winblad and H.M. Winsniewski, eds.) John Wiley and Sons: New York. 1-5
6. Geldmacher DS and Whitehouse PJ (1997). Differential diagnosis of Alzheimer's disease. Neurology 48, S2-S9
7. Schenk DB, Rydel RE, May P, Little S, Panetta J, Lieberburg I and Sinha S (1995). Therapeutic approaches related to amyloid-β peptide and Alzheimer's disease. J Med Chem 38, 4141-4154
8. Haley WE (1997). The family caregivers role in Alzheimer's disease. Neurology 48, S25-S29
9. Rogers SL and Friedhoff LT (1996). The efficacy and safety of donepezil in patients with Alzheimer's disease: Results of a US multicentre, randomized, double-blind, placebo-controlled trial. The Donepezil Study Group. Dementia 7, 293-303
10. Sano M, Ernesto C, Thomas RG, Klauber MR, Schafer K, Grundman M, Woodbury P, Growdon J, Cotman CW, Pfeiffer E, Schneider LS and Thai LJ (1997). A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease. The Alzheimer's Disease Cooperative Study [see comments]. New Eng J Med 336, 1216-1222
11. Davis KL, Thal LJ, Gamzu ER, Davis CS, Woolson RF, Gracon SI, Drachman DA, Schneider LS, Whitehouse PJ, Hoover TM, C MJ, H KC, S KD, L EN, V K, RS D and G TCS (1992). A double-blind, placebo-controlled multicenter study of tacrine for Alzheimer's disease. The Tacrine Collaborative Study Group [see comments]. New Eng J Med 327, 1253-1259
12. Ernst RL and Hay JW (1994). The US economic and social costs of Alzheimer's disease revisited. Am J Publ Health 84, 1261-1264
13. Rice DP, Fox PJ, Max W, Webber PA, Lindeman DA, Hauck WW and Segura E (1993). The economic burden of Alzheimer's disease care. Health Aff 12, 164-176
14. Alzheimer A (1906). Über einen eigenartigen schweren Erkrankungsprozeß der Hirnrinde. Neurol Centr 23, 1129-1136
15. Wischik CM, Novak M, Thogersen HC, Edwards PC, Runswick MJ, Jakes R, Walker JE, Milstein C, Rother M and Klug A (1988). Isolation of a fragment of tau derived from the core of the paired helical filament of Alzheimer's disease. Proc Natl Acad Sci USA 85, 4506-4510
16. Wischik C, Novak M, Edwards P, Klug A, Tichelaar W and Crowther R (1988). Structural characterization of the core of the paired helical filament of Alzheimer disease. Proc Natl Acad Sci USA 85, 4884-4888
17. Goedert M, Wischik CM, Crowther RA, Walker JE and Klug A (1988). Cloning and sequencing of the cDNA encoding a core protein of the paired helical filament of Alzheimer disease: identification as the microtubule-associated protein tau. Proc Natl Acad Sci USA 85, 4051-4055
18. Kang J, Lemaire H-G, Unterbeck A, Salbaum JM, Masters CL, Grzeschik K-H, Multhaup G, Beyreuther K and Muller-Hill B (1987). The precursor of Alzheimer's disease amyloid A4 protein resembles a cell-surface receptor. Nature 325, 733-736
19. Tanzi RE, Gusella JF, Watkins PC, Bruns GAB, St. George-Hyslop PH, Van Keuren ML, Patterson D, Pagan S, Kumit DM and Neve RL (1987). Amyloid β-protein gene: cDNA, mRNA distribution, and genetic linkage near the Alzheimer locus. Science 235, 880-884
20. Glenner GG and Wong CW (1984). Alzheimer's disease: Initial report of the purification and characterization of a novel cerebrovascular amyloid protein. Biochem Biophys Res Commun 120, 885-890
21. Selkoe DJ (1997). Alzheimer's disease: genotypes, phenotypes, and treatments. Science 275, 630-631
22. Hardy J (1997). Amyloid, the presenilins and Alzheimer's disease. Trends Neurosci 20, 154-159
23. Selkoe DJ (1994). Alzheimer's disease: A central role for amyloid. J Neuropath Exp Neurol 53, 438-447
24. Selkoe DJ (1996). Amyloid β-protein and the genetics of Alzheimer's disease. J Biol Chem 271, 18295-18298
25. Mattson MP (1997). Cellular actions of β-amyloid precursor protein and its soluble and fibrillogenic derivatives. Physiol Rev 77, 1081-1132
26. Hardy J (1997). The Alzheimer family of diseases - Many etiologies, one pathogenesis. Proc Natl Acad Sci USA 94, 2095-2097
27. Yankner BA (1996). New clues to Alzheimer's disease - Unraveling the roles of amyloid and tau. Nature Med 2, 850-852
28. Kisilevsky R (1996). Anti-amyloid drugs: Potential in the treatment of diseases associated with aging. Drugs Aging 8, 75-83
29. Larner AJ and Rossor MN (1997). Alzheimer's disease: towards therapeutic manipulation of the amyloid precursor protein and amyloid β-peptides. Exp Opin Ther Patents 7, 1115-1127
30. Kelly JW (1997). Amyloid fibril formation and protein misassembly: a structural quest for insights into amyloid and prion diseases. Structure 5, 595-600
31. Carrell RW and Lomas DA (1997). Conformational disease. Lancet 350, 134-138
32. Wisniewski HM and Terry RD (1973). Reexamination of the pathogenesis of the senile plaque. Prog Neuropath 2, 1-26
33. Terry RD, Gonatas NK and Weiss M (1964). Ultrastructural studies in Alzheimer's presenile dementia. Am J Pathol 44, 269-297
34. Dickson DW (1997). The pathogenesis of senile plaques. J Neuropathol Exp Neurol 56, 321-339
35. Kidd M (1964). Alzheimer's disease- An electron microscopical study. Brain 87, 307-320
36. Narang HK (1980). High-resolution electron microscopic analysis of the amyloid fibril in Alzheimer's disease. J Neuropath Exp Neurol 39, 621-631
37. Miyakawa T, Watanabe K and Katsuragi S (1986). Ultrastructure of amyloid fibrils in Alzheimer's disease and Down's syndrome. Virchows Arch [Cell Pathol] 52, 99-106
38. Vanley CT, Aguilar MJ, Kleinhenz RJ and Lagios MD (1981). Cerebral amyloid angiopathy. Human Path 12, 609-616
39. Yamaguchi H, Yamazaki T, Lemere CA, Frosch MP and Selkoe DJ (1992). Beta amyloid is focally deposited within the outer basement membrane in the amyloid angiopathy of Alzheimer's disease. Am J Pathol 141, 249-259
40. Yamaguchi H, Hirai S, Morimatsu M, Shoji M and Harigaya Y (1988). Diffuse type of senile plaques in the brains of Alzheimer-type dementia. Acta Neuropath 77, 113-119
41. Yamaguchi H, Nakazato Y, Hirai S, Shoji M and Harigaya Y (1989). Electron micrograph of diffuse plaques: Initial stage of senile plaque formation in the Alzheimer brain. Am J Pathol 135, 593-597
42. Yamazaki T, Yamaguchi H, Nakazato Y, Ishiguro K, Kawarabayashi T and Hirai S (1992). Ultrastructural characterization of cerebellar diffuse plaques in Alzheimer's disease. J Neuropath Exp Neurol 51, 281-286
43. Davies CA and Mann DMA (1993). Is the "preamyloid" of diffuse plaques in Alzheimer's disease really nonfibrillar? Am J Pathol 143, 1594-1605
44. Eanes ED and Glenner GG (1968). X-ray diffraction studies on amyloid filaments. J Histochem Cytochem 16, 673-677
45. Glenner GG and Wong CW (1984). Alzheimer's disease and Down's syndrome: Sharing of a unique cerebrovascular amyloid fibril protein. Biochem Biophys Res Commun 122, 1131-1135
46. Goldgaber D, Lerman MI, McBridge OW, V S and Gajdusek DC (1987). Characterization and chromosomal localization of a cDNA encoding brain amyloid of Alzheimer's disease. Science 235, 877-880
47. Robakis NK, Ramakrishna N, Wolfe G and Wisniewski HM (1987). Molecular cloning and characterization of a cDNA encoding the cerebrovascular and the neuritic plaque amyloid peptides. Proc Natl Acad Sci USA 84, 4190-4194
48. Masters CL, Simms G, Weinman NA, Multhaup G, McDonald BL and Beyreuther K (1985). Amyloid plaque core protein in Alzheimer disease and Down syndrome. Proc Natl Acad Sci USA 82, 4245-4249
49. Prelli F, Castaño E, Glenner GG and Frangione B (1988). Differences between vascular and plaque core amyloid in Alzheimer's disease. J Neurochem 51, 648-651
50. Joachim CL, Duffy LK, Morris JH and Selkoe DJ (1988). Protein chemical and immunocytochemical studies of meningovascular β-amyloid protein in Alzheimer's disease and normal aging. Brain Res 474, 100-111
51. Mori H, Takio K, Ogawara M and Selkoe DJ (1992). Mass spectrometry of purified amyloid β protein in Alzheimer's disease. J Biol Chem 267, 17082-17086
52. Miller DL, Papayannopoulos IA, Styles J and Bobin SA (1993). Peptide compositions of the cerebrovascular and senile plaque core amyloid deposits of Alzheimer's disease. Arch Biochem Biophys 301, 41-52
53. Roher AE, Lowenson JD, Clarke S, Woods AS, Cotter RJ, Gowing E and Ball MJ (1993). β-amyloid-(1-42) is a major component of cerebrovascular amyloid deposits: Implications for the pathology of Alzheimer disease. Proc Natl Acad Sci USA 90, 10836-10840
54. Naslund J, Schierhorn A, Hellman U, Lannfelt L, Roses AD, Tjernberg LO, Silberring J, Gandy SE, Winblad B, Greengard P, Nordstedt C and Terenius L (1994). Relative abundance of Alzheimer Aβ amyloid peptide variants in Alzheimer disease and normal aging. Proc Natl Acad Sci USA 91, 8378-8382
55. Kuo YM, Emmerling MR, Woods AS, Cotter RJ and Roher AE (1997). Isolation, chemical characterization, and quantitation of Aβ 3-pyroglutamyl peptide from neuritic plaques and vascular amyloid deposits. Biochem Biophys Res Commun 237, 188-191
56. Gowing E, Roher AE, Woods AS, Cotter RJ, Chaney M, Little SP and Ball MJ (1994). Chemical characterization of Aβ 17-42 peptide, a component of diffuse amyloid deposits of Alzheimer disease. J Biol Chem 269, 10987-10990
57. Lalowski M, Golabek A, Lemere CA, Selkoe DJ, Wisniewski HM, Beavis RC, Frangione B and Wisniewski T (1996). The "nonamyloidogenic" p3 fragment (Amyloid β17-42) is a major constituent of Down's syndrome cerebellar preamyloid. J Biol Chem 271, 33623-33631
58. Higgins LS, Murphy GM, Forno LS, Catalano R and Cordell B (1996). p3 β-amyloid peptide has a unique and potentially pathogenic immunohistochemical profile in Alzheimer's disease brain. Am J Pathol 149, 585-596
59. Iwatsubo T, Saido TC, Mann DMA, Lee VMY and Trojanowski JQ (1996). Full-length amyloid-β(1-42(43)) and amino-terminally modified and truncated amyloid-β42(43) deposit in diffuse plaques. Am J Pathol 149, 1823-1830
60. Shapira R, Austin GE and Mirra SS (1988). Neuritic plaque amyloid in Alzheimer's disease is highly racemized. J Neurochem 50, 69-74
61. Roher AE, Lowenson JD, Clarke S, Wolkow C, Wang R, Cotter RJ, Reardon I, Zurcher-Neely HA, Heinrikson RL, Ball MJ and Greenberg BD (1993). Structural alterations in the peptide backbone of β-amyloid core protein may account for its deposition and stability in Alzheimer's disease. J Biol Chem 268, 3072-3083
62. Selkoe DJ, Abraham CR, Podlisny MB and Duffy LK (1986). Isolation of low-molecular-weight proteins from amyloid plaque fibers in Alzheimer's disease. J Neurochem 146, 1820-1834
63. Ida N, Hartmann T, Pantel J, Schroder J, Zerfass R, Forstl H, Sandbrink R, Masters CL and Beyreuther K (1996). Analysis of heterogeneous βA4 peptides in human cerebrospinal fluid and blood by a newly developed sensitive western blot assay. J Biol Chem 271, 22908-22914
64. Seubert P, Vigo-Pelfrey C, Esch F, Lee M, Dovey H, Davis D, Sinha S, Schlossmacher MG, Whaley J, Swindlehurst C, McCormack R, Wolfert R, Selkoe DJ, Lieberburg I and Schenk D (1992). Isolation and quantitation of soluble Alzheimer's β-peptide from biological fluids. Nature 359, 325-327
65. Vigo-Pelfrey C, Lee D, Keim P, Lieberburg I and Schenk DB (1993). Characterization of β-amyloid peptide from human cerebrospinal fluid. J Neurochem 61, 1965-1968
66. Ghiso J, Calero M, Matsubara E, Governale S, Chuba J, Beavis R, Wisniewski T and Frangione B (1997). Alzheimer's soluble amyloid β is a normal component of human urine. FEBS Lett 408, 105-108
67. Haass C, Schlossmacher MG, Hung AY, Vigo-Pelfrey C, Mellon A, Ostaszewski BL, Lieberburg I, Koo EH, Schenk D, Teplow DB and Selkoe DJ (1992). Amyloid β-peptide is produced by cultured cells during normal metabolism. Nature 359, 322-5
68. Harigaya Y, Shoji M, Kawarabayashi T, Kanai M, Nakamura T, Iizuka T, Igeta Y, Saido TC, Sahara N, Mori H and Hirai S (1995). Modified amyloid β protein ending at 42 or 40 with different solubility accumulates in the brain of Alzheimer's disease. Biochem Biophys Res Commun 211, 1015-1022
69. 1-42/43) of amyloid β protein as a seed molecule in cerebral deposits of Alzheimer's disease. Biochem Biophys Res Commun 205, 834-842
70. Tabaton M, Nunzi MG, Xue R, Usiak M, Autilio-Gambetti L and Gambetti P (1994). Soluble amyloid β-protein is a marker of Alzheimer amyloid in brain but not in cerebrospinal fluid. Biochem Biophys Res Commun 200, 1598-1603
71. Suzuki N, Iwatsubo T, Odaka A, Ishibashi Y, Kitada C and Ihara Y (1994). High tissue content of soluble β1-40 is linked to cerebral amyloid angiopathy. Am J Pathol 145, 452-460
72. Teller JK, Russo C, Debusk LM, Angelini G, Zaccheo D, Dagnabricarelli F, Scartezzini P, Bertolini S, Mann DMA, Tabaton M and Gambetti P (1996). Presence of soluble amyloid β-peptide precedes amyloid plaque formation in Down's syndrome. Nature Med 2, 93-95
73. Russo C, Saido TC, DeBusk LM, Tabaton M, Gambetti P and Teller JK (1997). Heterogeneity of water-soluble amyloid β-peptide in Alzheimer's disease and Down's syndrome brains. FEBS Lett 409, 411-6
74. N3(pE), in senile plaques. Neuron 14, 457-466
75. Saido TC, Yamao-Harigaya W, Iwatsubo T and Kawashima S (1996). Amino- and carboxyl-terminal heterogeneity of β-amyloid peptides deposited in human brain. Neurosci Lett 215, 173-176
76. Cummings BJ, Pike CJ, Shankle R and Cotman CW (1996). β-amyloid deposition and other measures of neuropathology predict cognitive status in Alzheimer's disease. Neurobiol Aging 17, 921-933
77. Blessed G, Tomlinson BE and Roth M (1968). The association between quantitative measures of dementia and senile change in the cerebral grey matter of elderly subjects. Br J Psych 114, 797-811
78. McKee AC, Kosik KS and Kowall NW (1991). Neuritic pathology and dementia in Alzheimer's disease. Ann Neurol 30, 156-165
79. Dickson DW, Crystal HA, Bevona C, Honer W, Vincent I and Davies P (1995). Correlations of synaptic and pathological markers with cognition of the elderly. Neurobiol Aging 16, 285-298
80. He Y, Delaere P, Duyckaerts C, Wasowicz M, Piette F and Hauw JJ (1993). Two distinct ubiquitin immunoreactive senile plaques in Alzheimer's disease: relationship with the intellectual status in 29 cases. Acta Neuropath 86, 109-116
81. Terry RD, Masliah E, Salmon DP, Butters N, DeTeresa R, Hill R, Hansen LA and Katzman R (1991). Physical basis of cognitive alterations in Alzheimer's disease: synapse loss is the major correlate of cognitive impairment. Ann Neurol 30, 572-580
82. Cohen AS and Calkins E (1959). Electron microscopic observation on a fibrous component in amyloid of diverse origins. Nature 183, 1202-1203
83. Shirahama T and Cohen AS (1967). High-resolution electron microscopic analysis of the amyloid fibril. J Cell Biol 33, 679-708
84. Fraser PE, Duffy LK, O'Malley MB, Nguyen J, Inouye H and Kirschner DA (1991). Morphology and antibody recognition of synthetic β-amyloid peptides. J Neurosci Res 28, 474-485
85. Fraser PE, Nguyen JT, Surewicz WK and Kirschner DA (1991). pH-dependent structural transitions of Alzheimer amyloid peptides. Biophysical J 60, 1190-1201
86. Malinchik SB, Inouye H, Szumowski KE and Kirschner DA (1998). Structural analysis of Alzheimer's β(1-40) amyloid: Protofilament assembly of tubular fibrils. Biophysical J 74, 537-545
87. Serpell LC, Sunde M, Fraser PE, Luther PK, Morris EP, Sangren O, Lundgren E and Blake CC (1995). Examination of the structure of the transthyretin amyloid fibril by image reconstruction from electron micrographs. J Mol Biol 254, 113-118
88. Glenner GG, Eanes ED and Page DL (1972). The relation of the properties of Congo red-stained amyloid fibrils to the β-conformation. J Histochem Cytochem 20, 821-826
89. Kirschner DA, Abraham C and Selkoe DJ (1986). X-ray diffraction from intraneuronal paired helical filaments and extraneuronal amyloid fibers in Alzheimer's disease indicates cross-β conformation. Proc Natl Acad Sci USA 83, 503-507
90. Inouye H, Fraser PE and Kirschner DA (1993). Structure of β-crystallite assemblies formed by Alzheimer β-amyloid protein analogues: analysis by X-ray diffraction. Biophysical J 64, 502-519
91. Bonar L, Cohen AS and Skinner MM (1969). Characterization of the amyloid fibril as a cross-β protein. Proc Soc Exp Biol Med 131, 1373-1375
92. Pauling L and Corey R (1951). Configuration of polypeptide chains with favoured orientation around single bonds: two new pleated sheets. Proc Natl Acad Sci USA 37, 729-739
93. Geddes AJ, Parker KD, Atkins ED and Beighton E (1968). "Cross-β" conformation in proteins. J Mol Biol 32, 343-358
94. Benson MD and Uemichi T (1996). Transthyretin amyloidosis. Amyloid: Int J Exp Clin Invest 3, 44-56
95. Blake C and Serpell L (1996). Synchrotron X-ray studies suggest that the core of the transthyretin amyloid fibril is a continuous β-sheet helix. Structure 4, 989-998
96. Inouye H, Domingues FS, Dumas AM, Saraiva MJ, Lundgren E, Sandgren E and Kirschner DA (1998). X-ray analysis of transthyretin amyloid fibers from Met30 biopsy: Axially arrayed monomers constitute the protofibril. Amyloid: Int J Exp Clin Invest. In press
97. Chothia C (1973). Conformation of twisted β-pleated sheets in proteins. J Mol Biol 75, 295-302
98. Astbury WT, Dickinson S and Bailey K (1935). CCLXXIX. The X-ray interpretation of denaturation and the structure of the seed globulins. Biochem J 29, 2351-2360
99. Yoder MD, Keen NT and Jurnak F (1993). New domain motif: the structure of pectate lyase C, a secreted plant virulence factor. Science 260, 1503-1507
100. Sunde M, Serpell LC, Bartlam M, Fraser PE, Pepys MB and Blake CCF (1997). Common core structure of amyloid fibrils by synchrotron X-ray diffraction. J Mol Biol 273, 729-739
101. Pepys MB (1996). Amyloidosis. In: The Oxford Textbook of Medicine. (D.J. Weatherall, J.G.G. Ledingham and D.A. Warell, eds.) Oxford University Press: Oxford. 1512-1524
102. Creighton TE (1993). The folded conformation of globular proteins. In: Proteins: Structures and Molecular Properties. W. H. Freeman: New York. 201-260
103. Harper JD and Lansbury PT, Jr. (1997). Models of amyloid seeding in Alzheimer's disease and scrapie: mechanistic truths and physiological consequences of the time-dependent solubility of amyloid proteins. Ann Rev Biochem 66, 385-407
104. Castaño EM, Ghiso J, Prelli F, Gorevic PD, Migheli A and Frangione B (1986). In vitro formation of amyloid fibrils from two synthetic peptides of different lengths homologous to Alzheimer's disease β-protein. Biochem Biophys Res Commun 141, 782-789
105. Kirschner DA, Inouye Y, Duffy LK, Sinclair A, Lind M and Selkoe DJ (1987). Synthetic peptide homologous to β protein from Alzheimer disease forms amyloid-like fibrils in vitro. Proc Natl Acad Sci USA 84, 6953-6957
106. Gorevic PD, Castaño EM, Sarma R and Frangione B (1987). Ten to fourteen residue peptides of Alzheimer's disease protein are sufficient for amyloid fibril formation and its characteristic X-ray diffraction pattern. Biochem Biophys Res Commun 147, 854-862
107. Hilbich C, Kisters-Woike B, Reed J, Masters CL and Beyreuther K (1991). Human and rodent sequence analogs of Alzheimer's amyloid βA4 share similar properties and can be solubilized in buffers of pH 7.4. Eur J Biochem 201, 61-69
108. Wood SJ, Wetzel R, Martin JD and Hurle MR (1995). Prolines and amyloidogenicity in fragments of the Alzheimer's peptide β/A4. Biochemistry 34, 724-730
109. Halverson K, Fraser PE, Kirschner DA and Lansbury PT, Jr. (1990). Molecular determinants of amyloid deposition in Alzheimer's disease: Conformational studies of synthetic β-protein fragments. Biochemistry 29, 2639-2644
110. Burdick D, Soreghan B, Kwon M, Kosmoski J, Knauer M, Henschen A, Yates J, Cotman C and Glabe C (1992). Assembly and aggregation properties of synthetic Alzheimer's A4/β amyloid peptide analogs. J Biol Chem 267, 546-554
111. Hilbich C, Kisters-Woike B, Reed J, Masters CL and Beyreuther K (1991). Aggregation and secondary structure of synthetic amyloid βA4 peptides of Alzheimer's disease. J Mol Biol 218, 149-163
112. Fraser PE, McLachlan DR, Surewicz WK, Mizzen CA, Snow AD, Nguyen JT and Kirschner DA (1994). Conformation and fibrillogenesis of Alzheimer Aβ peptides with selected substitution of charged residues. J Mol Biol 244, 64-73
113. Pike CJ, Walencewicz-Wasserman AJ, Kosmoski J, Cribbs DH, Glabe CG and Cotman CW (1995). Structure-activity analyses of β-amyloid peptides: Contributions of the β25-35 region to aggregation and neurotoxicity. J Neurochem 64, 253-265
114. Hilbich C, Kisters-Woike B, Reed J, Masters CL and Beyreuther K (1992). Substitutions of hydrophobic amino acids reduce the amyloidogenicity of Alzheimer's disease βA4 peptides. J Mol Biol 228, 460-473
115. Teplow DB, Lomakin A, Benedek GB, Kirschner DA and Walsh DM (1997). Effects of β-protein mutations on amyloid fibril nucleation and elongation. In: Alzheimer's Disease: Biology, Diagnosis and Therapeutics. (K. Iqbal, B. Winblad, T. Nishimura, M. Takeda and H.M. Wisniewski, eds.) John Wiley & Sons Ltd.: Chichester, England. 311-319
116. Hendriks L, van Duijn CM, Cras P, Cruts M, Van Hul W, van Harskamp F, Warren A, McInnis MG, Antonarakis SE, Martin JJ, Hofman A and Van Broeckhoven C (1992). Presenile dementia and cerebral haemorrhage linked to a mutation at codon 692 of the β-amyloid precursor protein gene. Nature Genet 1, 218-221
117. Clements A, Allsop D, Walsh DM and Williams CH (1996). Aggregation and metal-binding properties of mutant forms of the amyloid Aβ peptide of Alzheimer's disease. J Neurochem 66, 740-747
118. Fraser PE, Nguyen JT, Inouye H, Surewicz WK, Selkoe DJ, Podlisny MB and Kirschner DA (1992). Fibril formation by primate, rodent, and Dutch-hemorrhagic analogues of Alzheimer amyloid β-protein. Biochemistry 31, 10716-10723
119. Barrow CJ, Yasuda A, Kenny PTM and Zagorski M (1992). Solution conformations and aggregational properties of synthetic amyloid β-peptides of Alzheimer's disease. J Mol Biol 225, 1075-1093
120. Dyson HJ, Rance M, Houghten RA, Wright PE and Lerner RA (1988). Folding of immunogenic peptide fragments of proteins in water solution. II. The nascent helix. J Mol Biol 201, 201-217
121. Levy E, Carman MD, Fernandez-Madrid IJ, Power MD, Lieberburg I, van Duinen SG, Bots GTAM, Luyendijk W and Frangione B (1990). Mutation of the Alzheimer's disease amyloid gene in hereditary cerebral hemorrhage, Dutch-type. Science 248, 1124-1126
122. Teplow DB (1998). The biophysics of amyloid β-protein fibrillogenesis. In: The Molecular Biology of Alzheimer's Disease-Genes and Mechanisms Involved in Amyloid Generation. (C. Haass, ed.) Harwood Academic Publishers: Amsterdam, in press
123. Fabian H, Szendrei GI, Mantsch HH and Otvos L, Jr. (1993). Comparative analysis of human and Dutch-type Alzheimer β-amyloid peptides by infrared spectroscopy and circular dichroism. Biochem Biophys Res Commun 191, 232-239
124. 23 residue affects the aggregation properties of Alzheimer amyloid β protein analogues. J Biol Chem 269, 10205-10208
125. Mori H, Ishii K, Tomiyama T, Furiya Y, Sahara N, Asano S, Endo N, Shirasawa T and Takio K (1994). Racemization: Its biological significance on neuropathogenesis of Alzheimer's disease. Tohoku J Exp Med 174, 251-262
126. Wood SJ, Maleeff B, Hart T and Wetzel R (1996). Physical, morphological and functional differences between pH 5.8 and 7.4 aggregates of the Alzheimer's amyloid peptide Aβ. J Mol Biol 256, 870-877
127. Fabian H, Szendrei GI, Mantsch HH, Greenberg BD and Otvos L, Jr. (1994). Synthetic post-translationally modified human Aβ peptide exhibits a markedly increased tendency to form β-pleated sheets in vitro. Eur J Biochem 221, 959-964
128. Barrow CJ and Zagorski MG (1991). Solution structures of β peptide and its constituent fragments: relation to amyloid deposition. Science 253, 179-182
129. Talafous J, Marcinowski KJ, Klopman G and Zagorski MG (1994). Solution structure of residues 1-28 of the amyloid β-peptide. Biochemistry 33, 7788-7796
130. Sticht H, Bayer P, Willbold D, Dames S, Hilbich C, Beyreuther K, Frank RW and Rosch P (1995). Structure of amyloid A4-(1-40)-peptide of Alzheimer's disease. Eur J Biochem 233, 293-298
131. Zagorski MG and Barrow CJ (1992). NMR studies of amyloid β-peptides: proton assignments, secondary structure, and mechanism of an α-helix->β-sheet conversion for a homologous, 28-residue, N-terminal fragment. Biochemistry 31, 5621-5631
132. Lansbury PT, Jr., Costa PR, Griffiths JM, Simon EJ, Auger M, Halverson KJ, Kocisko DA, Hendsch ZS, Ashburn TT, Spencer RG, Tidor B and Griffin RG (1995). Structural model for the β-amyloid fibril based on interstrand alignment of an antiparallel-sheet comprising a C-terminal peptide. Nature Struct Biol 2, 990-998
133. Jarrett JT, Berger EP and Lansbury PT, Jr. (1993). The carboxy terminus of the β amyloid protein is critical for the seeding of amyloid formation: Implications for the pathogenesis of Alzheimer's disease. Biochemistry 32, 4693-4697
134. Jarrett JT, Berger EP and Lansbury PT, Jr. (1993). The C-terminus of the β protein is critical in amyloidogenesis. Ann N Y Acad Sci, 144-148
135. Sorimachi K, Craik DJ, Lloyd EJ, Beyreuther K and Masters CL (1990). Identification of a β-turn in the tertiary structure of a peptide fragment of the Alzheimer amyloid protein. Biochem Int 22, 447-454
136. Sorimachi K and Craik DJ (1994). Structure determination of extracellular fragments of amyloid proteins involved in Alzheimer's disease and Dutch-type hereditary cerebral haemorrhage with amyloidosis. Eur J Biochem 219, 237-251
137. Heller J, Kolbert AC, Larsen R, Ernst M, Bekker T, Baldwin M, Prusiner SB, Pines A and Wemmer DE (1996). Solid-state NMR studies of the prion protein H1 fragment. Protein Sci 5, 1655-1661
138. Jackson M and Mantsch HH (1991). Beware of proteins in DMSO. Biochim Biophys Acta 1078, 231-235
139. 1H NMR of Aβ amyloid peptide congeners in water solution. Conformational changes correlate with plaque competence. Biochemistry 34, 5191-5200
140. Maggio JE, Stimson ER, Ghilardi JR, Alln CJ, Dahl CE, Whitcomb DC, Vigna SR, Vinters HV, Labenski ME and Mantyh PW (1992). Reversible in vitro growth of Alzheimer disease β-amyloid plaques by deposition of labeled amyloid peptide. Proc Natl Acad Sci USA 89, 5462-5466
141. Soto C, Castaño EM, Frangione B and Inestrosa NC (1995). The α-helical to β-strand transition in the amino-terminal fragment of the amyloid β-peptide modulates amyloid formation. J Biol Chem 270, 3063-3067
142. Tomski SJ and Murphy RM (1992). Kinetics of aggregation of synthetic β-amyloid peptide. Arch Biochem Biophys 294, 630-638
143. Soto C and Frangione B (1995). Two conformational states of amyloid β-peptide: implications for the pathogenesis of Alzheimer's disease. Neurosci Lett 186, 115-118
144. Soto C, Castaño EM, Kumar RA, Beavis RC and Frangione B (1995). Fibrillogenesis of synthetic amyloid-β peptides is dependent on their initial secondary structure. Neurosci Lett 200, 105-108
145. Jarrett JT and Lansbury PT, Jr (1993). Seeding "one-dimensional crystallization" of amyloid: A pathogenic mechanism in Alzheimer's disease and scrapie? Cell 73, 1055-1058
146. Andreu JM and Timasheff SN (1986). The measurement of cooperative protein self-assembly by turbidity and other techniques. Meth Enzymol 130, 47-59
147. Simmons LK, May PC, Tomaselli KJ, Rydel RE, Fuson KS, Brigham EF, Wright S, Lieberburg I, Becker GW, Brems DN and Li WY (1994). Secondary structure of amyloid β peptide correlates with neurotoxic activity in vitro. Molecular Pharm 45, 373-379
148. Hewlett DR, Jennings KH, Lee DC, Clark MS, Brown F, Wetzel R, Wood SJ, Camilleri P and Roberts GW (1995). Aggregation state and neurotoxic properties of Alzheimer beta-amyloid peptide. Neurodegeneration 4, 23-32
149. Shen CL, Fitzgerald MC and Murphy RM (1994). Effect of acid predissolution on fibril size and fibril flexibility of synthetic β-amyloid peptide. Biophysical J 67, 1238-1246
150. Pecora R (1985). Dynamic Light Scattering: Applications of Photon Correlation Spectroscopy, Plenum Press, New York, NY
151. Tracy MA and Pecora R (1992). Dynamics of rigid and semi-rigid rodlike polymers. Ann Rev Phys Chem 43, 525-557
152. Shen CL and Murphy RM (1995). Solvent effects on self-assembly of β-amyloid peptide. Biophysical J 69, 640-651
153. Döbeli H, Draeger N, Huber G, Jakob P, Schmidt D, Seilheimer B, Stuber D, Wipf B and Zulauf M (1995). A biotechnological method provides access to aggregation competent monomeric Alzheimer's 1-42 residue amyloid peptide. Bio/Technology 13, 988-993
154. Seilheimer B, Bohrmann B, Bondolfi L, Muller F, Stuber D and Döbeli H (1997). The toxicity of the Alzheimer's β-amyloid peptide correlates with a distinct fiber morphology. J Struct Biol 119, 59-71
155. Mant CT and Hodges RS (1991). Effects of HPLC solvents and hydrophobic matrices on denaturation of proteins. In: High-performance Liquid Chromatography of Peptides and Proteins: Separation, Analysis, and Conformation. (C.T. Mant and R.S. Hodges, eds.) CRC Press: Boca Raton. 437-450
156. Benedek K, Dong S and Karger BL (1984). Kinetics of unfolding of proteins on hydrophobic surfaces in reversed-phase liquid chromatography. J Chromatogr 317, 227-243
157. Bradbury EM, Crane-Robinson C and Temussi LP (1973). Nuclear magnetic resonance studies of a polypeptide in a nonprotonating solvent system. J Am Chem Soc 95, 1683-1684
158. 1H nuclear magnetic resonance study of enkephalin amides. Biochemistry 26, 7856-7863
159. Kaneko I (1997). Conformations of β-amyloid in solution - Reply. J Neurochem 68, 438-439
160. Walsh DM, Lomakin A, Benedek GB, Condron MM and Teplow DB (1997). Amyloid β-protein fibrillogenesis - Detection of a protofibrillar intermediate. J Biol Chem 272, 22364-22372
161. Soreghan B, Kosmoski J and Glabe C (1994). Surfactant properties of Alzheimer's Aβ peptides and the mechanism of amyloid aggregation. J Biol Chem 269, 28551-28554
162. Bush AI, Pettingell WHJ, de Paradis M and Tanzi RE (1994). Modulation of Aβ adhesiveness and secretase site cleavage by zinc. J Biol Chem 269, 12152-12158
163. Roher AE, Chaney MO, Kuo YM, Webster SD, Stine WB, Haverkamp LJ, Woods AS, Cotter RJ, Tuohy JM, Krafft GA, Bonnell BS and Emmerling MR (1996). Morphology and toxicity of Aβ(1-42) dimer derived from neuritic and vascular amyloid deposits of Alzheimer's disease. J Biol Chem 271, 20631-20635
164. Tseng BP, Esler WP, Stimson ER, Ghilardi JR, Vinters HV, Mantyh PW and Maggio JE (1998). Growth of Alzheimer's disease brain amyloid plaques by deposition of soluble Aβ peptide is independent of solution-phase assembly. To be submitted for publication
165. Esler WP, Stimson ER, Ghilardi JR, Vinters HV, Lee JP, Mantyh PW and Maggio JE (1996). In vitro growth of Alzheimer's disease β-amyloid plaques displays first-order kinetics. Biochemistry 35, 749-57
166. Naiki H and Nakakuki K (1996). First-order kinetic model of Alzheimer's β-amyloid fibril extension in vitro. Lab Invest 74, 374-383
167. Cohen RJ and Benedek GB (1975). Immunoassay by light scattering spectroscopy. Immunochemistry 12, 349-351
168. Lomakin A, Chung DS, Benedek GB, Kirschner DA and Teplow DB (1996). On the nucleation and growth of amyloid β-protein fibrils - Detection of nuclei and quantitation of rate constants. Proc Natl Acad Sci USA 93, 1125-1129
169. Lomakin A, Teplow DB, Kirschner DA and Benedek GB (1997). Kinetic theory of fibrillogenesis of amyloid β-protein. Proc Natl Acad Sci USA 94, 7942-7947
170. LeVine H, III (1995). Soluble multimeric Alzheimer β(1-40) pre-amyloid complexes in dilute solution. Neurobiol Aging 16, 755-764
171. Garzon-Rodriguez W, Sepulveda-Becerra M, Milton S and Glabe CG (1997). Soluble amyloid Aβ-(1-40) exists as a stable dimer at low concentrations. J Biol Chem 272, 21037-21044
172. Harper JD, Wong SS, Lieber CM and Lansbury PT (1997). Observation of metastable Aβ amyloid protofibrils by atomic force microscopy. Chem Biol 4, 119-125
173. Harper JD, Lieber CM and Lansbury PT (1997). Atomic force microscopic imaging of seeded fibril formation and fibril branching by the Alzheimer's disease amyloid-β protein. Chem Biol 4, 951-959
174. Stine WB, Jr., Snyder SW, Ladror US, Wade WS, Miller MF, Perun TJ, Holzman TF and Krafft GA (1996). The nanometer-scale structure of amyloid-β visualized by atomic force microscopy. J Prot Chem 15, 193-203
175. Strittmatter WJ and Roses AD (1996). Apolipoprotein E and Alzheimer's disease. Ann Rev Neurosci 19, 53-77
176. Schmechel DE, Saunders AM, Strittmatter WJ, Crain BJ, Hulette CM, Joo SH, Pericak-Vance MA, Goldgaber D and Roses AD (1993). Increased amyloid β-peptide deposition in cerebral cortex as a consequence of apolipoprotein E genotype in late-onset Alzheimer disease. Proc Natl Acad Sci USA 90, 9649-9653
177. Goate A, Chartier-Harlin M-C, Mullan M, Brown J, Crawford F, Fidani L, Giuffra L, Haynes A, Irving N, James L, Mant R, Newton P, Rooke K, Roques P, Talbot C, Pericak-Vance M, Roses A, Williamson R, Rossor M, Owen M and Hardy J (1991). Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease. Nature 349, 704-706
178. Bales KR, Verina T, Dodel RC, Du YS, Altstiel L, Bender M, Hyslop P, Johnstone EM, Little SP, Cummins DJ, Piccardo P, Ghetti B and Paul SM (1997). Lack of apolipoprotein E dramatically reduces amyloid β-peptide deposition. Nature Genet 17, 263-264
179. Naslund J, Thyberg J, Tjernberg LO, Wernstedt C, Karlstrom AR, Bogdanovic N, Gandy SE, Lannfelt L, Terenius L and Nordstedt C (1995). Characterization of stable complexes involving apolipoprotein E and the amyloid β-peptide in Alzheimer's disease brain. Neuron 15, 219-228
180. Strittmatter WJ, Weisgraber KH, Huang DY, Dong LM, Salvesen GS, Pericak-Vance M, Schmechel D, Saunders AM, Goldgaber D and Roses AD (1993). Binding of human apolipoprotein E to synthetic amyloid β-peptide: isoform-specific effects and implications for late-onset Alzheimer disease. Proc Natl Acad Sci USA 90, 8098-8102
181. Strittmatter WJ, Saunders AM, Schmechel D, Pericak-Vance M, Enghild J, Salvesen GS and Roses AD (1993). Apolipoprotein E: high-avidity binding to β-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease. Proc Natl Acad Sci USA 90, 1977-1981
182. Wisniewski T, Golabek A, Matsubara E, Ghiso J and Frangione B (1993). Apolipoprotein E: binding to soluble Alzheimer's β-amyloid. Biochem Biophys Res Commun 192, 359-365
183. Wisniewski T, Castaño EM, Golabek A, Vogel T and Frangione B (1994). Acceleration of Alzheimer's fibril formation by apolipoprotein E in vitro. Am J Pathol 145, 1030-1035
184. Sanan DA, Weisgraber KH, Russell SJ, Mahley RW, Huang D, Saunders A, Schmechel D, Wisniewski T, Frangione B, Roses AD and Strittmatter WJ (1994). Apolipoprotein E associates with β-amyloid peptide of Alzheimer's disease to form novel monofibrils. Isoform apoE4 associates more efficiently than apoE3. J Clin Invest 94, 860-869
185. 1-antichymotrypsin and apolipoprotein E promote assembly of Alzheimer β-protein into filaments. Nature 372, 92-94
186. Castaño EM, Prelli F, Wisniewski T, Golabek A, Kumar RA, SotoC and Frangione B (1995). Fibrillogenesis in Alzheimer's disease of amyloid β-peptides and apolipoprotein E. Biochem J 306, 599-604
187. Golabek AA, Soto C, Vogel T and Wisniewski T (1996). The interaction between apolipoprotein E and Alzheimer's amyloid β-peptide is dependent on β-peptide conformation. J Biol Chem 271, 10602-10606
188. Evans KC, Berger EP, Cho CG, Weisgraber KH and Lansbury PT (1995). Apolipoprotein E is a kinetic but not a thermodynamic inhibitor of amyloid formation: Implications for the pathogenesis and treatment of Alzheimer's disease. Proc Natl Acad Sci USA 92, 163-161
189. Wood SJ, Chan W and Wetzel R (1996). Seeding of Aβ fibril formation is inhibited by all three isotypes of apolipoprotein E. Biochemistry 35, 12623-12628
190. Schwarzman AL, Gregori L, Vitek MP, Lyubski S, Strittmatter WJ, Enghilde JJ, Bhasin R, Silverman J, Weisgraber KH, Coyle PK, Zagorski MG, Talafous J, Eisenberg M, Saunders AM, Roses AD and Goldgaber D (1994). Transthyretin sequesters amyloid beta protein and prevents amyloid formation. Proc Natl Acad Sci USA 91, 8368-8372
191. Naiki H, Gejyo F and Nakakuki K (1997). Concentration-dependent inhibitory effects of apolipoprotein E on Alzheimer's β-amyloid fibril formation in vitro. Biochemistry 36, 6243-6250
192. Aksenov MY, Aksenova MV, Carney JM and Butterfield DA (1996). α1-Antichymotrypsin interaction with Aβ(1-42) does not inhibit fibril formation but attenuates the peptide toxicity. Neurosci Lett 217, 117-120
193. Fraser PE, Nguyen JT, McLachlan DR, Abraham CR and Kirschner DA (1993). α1-Antichymotrypsin binding to Alzheimer Aβ peptides is sequence specific and induces fibril disaggregation in vitro. J Neurochem 61, 298-305
194. Eriksson S, Janciauskiene S and Lannfelt L (1995). α1-Antichymotrypsin regulates Alzheimer β-amyloid peptide fibril formation. Proc Natl Acad Sci USA 92, 2313-2317
195. Webster S and Rogers J (1996). Relative efficacies of amyloid β peptide (Aβ) binding proteins in Aβ aggregation. J Neurosci Res 46, 58-66
196. Schwarzman AL and Goldgaber D (1996). Interaction of transthyretin with amyloid β-protein: binding and inhibition of amyloid formation. Ciba Foundation Symposium 199, 146-164
197. Biere AL, Ostaszewski B, Stimson ER, Hyman BT, Maggio JE and Selkoe DJ (1996). Amyloid β-peptide is transported on lipoproteins and albumin in human plasma. J Biol Chem 271, 32916-32922
198. 1-42) and forms slowly sedimenting Aβ complexes that cause oxidative stress. Exp Neurol 136, 22-31
199. Zlokovic BV, Martel CL, Matsubara E, McComb JG, Zheng G, McCluskey RT, Frangione B and Ghiso J (1996). Glycoprotein 330/megalin: Probable role in receptor-mediated transport of apolipoprotein J alone and in complex with Alzheimer disease amyloid β at the blood-brain and blood-cerebrospinal fluid barriers. Proc Natl Acad Sci USA 93, 4229-4234
200. Golabek A, Marques MA, Lalowski M and Wisniewski T (1995). Amyloid β binding proteins in vitro and in normal human cerebrospinal fluid. Neurosci Lett 191, 79-82
201. Kowall NW and Kosik KS (1987). The cytoskeletal pathology of Alzheimer's disease is characterized by aberrant tau distribution. Ann Neurol 22, 639-643
202. Matsubara E, Soto C, Governale S, Frangione B and Ghiso J (1996). Apolipoprotein J and Alzheimers amyloid β solubility. Biochem J 316, 671-679
203. Ghiso J, Matsubara E, Koudinov A, Choi-Miura NH, Tomita M, Wisniewski T and Frangione B (1993). The cerebrospinal-fluid soluble form of Alzheimer's amyloid beta is complexed to SP-40,40 (apolipoprotein J), an inhibitor of the complement membrane-attack complex. Biochem J 293, 27-30
204. Koudinov A, Matsubara E, Frangione B and Ghiso J (1994). The soluble form of Alzheimer's amyloid beta protein is complexed to high density lipoprotein 3 and very high density lipoprotein in normal human plasma. Biochem Biophys Res Commun 205, 1164-1171
205. Janciauskiene S, Garcia de Frutos P, Carlemalm E, Dahlback B and Eriksson S (1995). Inhibition of Alzheimer β-peptide fibril formation by serum amyloid P component. J Biol Chem 270, 26041-26044
206. 2+-dependent binding of human serum amyloid P component to Alzheimer's β-amyloid peptide. J Biol Chem 270, 10392-10394
207. Webster S, O'Barr S and Rogers J (1994). Enhanced aggregation and β structure of amyloid β peptide after coincubation with C1q. J Neurosci Res 39, 448-456
208. Bronfman FC, Garrido J, Alvarez A, Morgan C and Inestrosa NC (1996). Laminin inhibits amyloid-β-peptide fibrillation. Neurosci Lett 218, 201-203
209. Dudek SM and Johnson G (1994). Transglutaminase facilitates the formation of polymers of the β-amyloid peptide. Brain Res 651, 129-133
210. 1-42 amyloidogenesis. FEBS Lett 416, 117-121
211. Alvarez A, Bronfman F, Perez CA, Vicente M, Garrido J and Inestrosa NC (1995). Acetylcholinesterase, a senile plaque component, affects the fibrillogenesis of amyloid-β-peptides. Neurosci Lett 201, 49-52
212. Choo-Smith LP and Surewicz WK (1997). The interaction between Alzheimer amyloid β(1-40) peptide and ganglioside GM1-containing membranes. FEBS Lett 402, 95-98
213. Guptabansal R, Frederickson RCA and Brunden KR (1995). Proteoglycan-mediated inhibition of Aβ proteolysis - A potential cause of senile plaque accumulation. J Biol Chem 270, 18666-18671
214. Castillo GM, Ngo C, Cummings J, Wight TN and Snow AD (1997). Perlecan binds to the β-amyloid proteins (Aβ) of Alzheimer's disease, accelerates Aβ fibril formation, and maintains Aβ fibril stability. J Neurochem 69, 2452-2465
215. Snow AD, Lara S, Nochlin D and Wight TN (1989). Cationic dyes reveal proteoglycans structurally integrated within the characteristic lesions of Alzheimer's disease. Acta Neuropath 78, 113-123
216. Snow AD and Castillo GM (1997). Specific proteoglycans as potential causative agents and relevant targets for therapeutic intervention in Alzheimer's disease and other amyloidoses. Amyloid: Int J Exp Clin Invest 4, 135-141
217. Mantyh PW, Ghilardi JR, Rogers S, DeMaster E, Allen CJ, Stimson ER and Maggio JE (1993). Aluminum, iron, and zinc ions promote aggregation of physiological concentrations of β-amyloid peptide. J Neurochem 61, 1171-1174
218. Kawahara M, Muramoto K, Kobayashi K, Mori H and Kuroda Y (1994). Aluminum promotes the aggregation of Alzheimer's amyloid β-protein in vitro. Biochem Biophys Res Commun 198, 531-535
219. Kuroda Y and Kawahara M (1994). Aggregation of amyloid β-protein and its neurotoxicity: Enhancement by aluminum and other metals. Tohoku J Exp Med 174, 263-268
220. Bush AI, Pettingell WH, Multhaup G, Paradis MD, Vonsattel JP, Gusella JF, Beyreuther K, Masters CL and Tanzi RE (1994). Rapid induction of Alzheimer Aβ amyloid formation by zinc. Science 265, 1464-1467
221. Esler WP, Stimson ER, Jennings JM, Ghilardi JR, Mantyh PW and Maggio JE (1996). Zinc-induced aggregation of human and rat β-amyloid peptides in vitro. J Neurochem 66, 723-732
222. Wilson DM and Binder LI (1997). Free fatty acids stimulate the polymerization of tau and amyloid β peptides. In vitro evidence for a common effector of pathogenesis in Alzheimer's disease. Am J Pathol 150, 2181-2195
223. Maggio JE, Esler WP, Stimson ER, Jennings JM, Ghilardi JR and Mantyh PW (1995). Zinc and Alzheimer's disease [letter; comment]. Science 268, 1920-1921; discussion 1921-1923